[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"En Chu Kong Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":113},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100652140","machine-learning-for-evaluating-and-diagnosing-temporomandibular-disorders-100652140",false,"NCT07771296","Machine Learning for Evaluating and Diagnosing Temporomandibular Disorders","Development of an Integrated Evaluation-to-Treatment Framework to Enhance Clinical Efficiency and Effectiveness in Temporomandibular Disorders","Inclusion Criteria:\n\n* Patients diagnosed with temporomandibular disorders (TMDs) screened by the Department of Dentistry, Division of Oral and Maxillofacial Surgery at En Chu Kong Hospital, who have failed to respond to analgesic treatment for at least one week.\n* Patients clinically examined and identified as having pain predominantly originating from muscles associated with mandibular movement.\n* Patients aged between 18 and 70 years (inclusive) with full legal capacity.\n* Patients who are willing to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Patients meeting any of the following clinical scale thresholds: Generalized Anxiety Disorder-7 (GAD-7)≥ 10, Patient Health Questionnaire-9 (PHQ-9) ≥ 15, Patient Health Questionnaire-15 (PHQ-15) ≥ 10, or Pittsburgh Sleep Quality Index (PSQI) \\> 5.\n* Patients with tumors of the temporomandibular joint (TMJ) or head and neck region.\n* Patients with acute or chronic infections.\n* Patients with a history of neuropathy or stroke.\n* Patients with a history of head and neck trauma.\n* Patients diagnosed with fibromyalgia.\n* Patients diagnosed with autoimmune or rheumatic diseases.\n* Patients diagnosed with irritable bowel syndrome (IBS).\n* Patients with claustrophobia (unable to undergo MRI examination).\n* Women who are pregnant or lactating, or parents currently in the infant care\u002Fnursing period.\n* Patients who have received invasive treatment for temporomandibular joint disorders within the past 3 months.","ALL","18 Years","70 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to improve clinical efficiency and effectiveness in treating Temporomandibular Disorders (TMD). The researchers will integrate machine learning technology with clinical examination data, CBCT, and MRI to identify the core underlying issues of each patient. Based on this precise, AI-assisted diagnosis, the study will implement a tailored treatment framework. The final goal is to develop predictive algorithms that can determine MRI necessity while ensuring that clinical interventions are highly targeted, efficient, and successful.",[27,28,29],"Temporomandibular Disorders (TMD)","TMJ Disorder","TMJ Pain",[31,32,33,34,35,36,37,38],"Machine Learning","Cone-Beam Computed Tomography","CBCT","Magnetic Resonance Imaging","MRI","Proprioceptive Training","low level laser","Laser Acupuncture","NOT_YET_RECRUITING","2026-08-18",{"date":42,"type":43},"2026-08-20","ACTUAL",{"date":45,"type":21},"2026-10-05",{"date":47,"type":21},"2027-07-31",{"name":49,"class":50},"En Chu Kong Hospital","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100581438","phase-2-herbal-ointment-in-treating-atopic-dermatitis-topically-100581438","NCT06850311","Herbal Ointment in Treating Atopic Dermatitis Topically","Efficacy and Safety of Herbal Topical Ointment in Treating Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Between 18 and 65 years old, female or male.\n2. Atopic dermatitis fulfilling the diagnostic criteria of Hanifin\\&Rajka.\n3. Atopic dermatitis involving \\\u003C10% of BSA. (Base on the BSA result of Screening)\n4. An Investigator's Global Assessment (IGA) score of 2, 3 or 4 which corresponds to mild, moderate or severe disease. (Base on the IGA result of Screening)\n5. Female patients of child-bearing age with negative pregnancy test at screening.\n6. Female patients of child-bearing age that agree to continue using birth control measures approved by the investigator and agree not to lactate for the duration of the study.\n\nAgree to only receive stable doses of an additive-free, basic bland emollient for at least 7 days before baseline (day0) Willing to comply with study protocol and agree to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Having a history of topical or systematical hypersensitivity to herbal or its excipient (e.g. vehicle) in ointment\n2. Undergoing phototherapy (e.g. UVB, PUVA) or systemic therapy (e.g. Immunosuppressive agents) within 30 days.\n3. Having used topical or oral therapy (e.g. topical corticosteroids, antibiotic, TCM) for dermatitis within 7 days before the first application of the study medication.\n4. Having a significant concurrent disease, such as: significant abnormalities in hematology, severe uncontrolled metabolic syndrome (e.g., hypertension, diabetes mellitus, metabolic arthritis, hyperthyroidism), psychiatric disease, cancer or AIDS.\n5. Having abnormal liver or renal function (AST\u002FALT \\>3 x ULN, creatinine \\>2.0 mg\u002Fdl).\n6. Women who are lactating, pregnant or preparing to be pregnant.","65 Years",{"count":60,"type":21},66,[62,63],"PHASE2","PHASE3","Atopic dermatitis (AD), also known as atopic eczema, is a chronic inflammatory skin disorder. The current first-line recommended treatment for AD is the use of emollients, topical corticosteroids (TCS), and oral antihistamines if necessary. However, patients often have side effects like skin atrophy and telangiectasia. And there were plenty of herbal medicine which are beneficial to atopic dermatitis in ancient Chinese medicine books and records. Therefore, the purpose of this study is to develop a new topical application of traditional Chinese medicine and evaluate its clinical efficacy in AD patients. In human trial, 66 Subjects diagnosed as AD will be enrolled and treated with Sophora flavescens Aiton topical ointment. After treatment we will estimate the efficacy and record adverse events to conduct statistically analysis.\n\nThe 1st year project: (1) Expect to enroll 66 clinical subjects of AD. (2) Evaluate subjects 'symptom and proceed herbal ointment treatment. (3) Record treatment responses including adverse effect. (4) Conduct statistically analysis.\n\nThe 2nd year project: (1) Completing enrollment of 66 clinical subjects of AD. (2) Finish evaluation and treatment of all subjects. (3) Statistically analysis all collecting data (4) Discuss and analyze the outcome.",[66,67,68,69,70,71,72,73],"Atopic Dermatitis","Atopic Dermatitis (AD)","Atopic Dermatitis (Eczema)","Atopic Dermatitis Eczema","TCM","Skin Diseases","Skin Diseases, Eczematous","Skin Diseases, Genetic","RECRUITING","2025-02-23",{"date":77,"type":43},"2025-02-27",{"date":79,"type":21},"2025-03-01",{"date":81,"type":21},"2027-04-01",{"name":49,"class":50},1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":83},"100474238","efficacy-and-safety-of-allium-ureteral-stent-for-treating-refractory-ureteral-stricture-100474238","NCT05455307","Efficacy and Safety of Allium Ureteral Stent for Treating Refractory Ureteral Stricture","Efficacy and Safety of Self-expanding Ureteral Stent for Treating Refractory Ureteral Stricture: Results of a Multicenter Experience","Allium","Inclusion Criteria:\n\n* refractory ureteral stricture after at least two times of ureteral dilation\n\nExclusion Criteria:\n\n* poor cardiovascular function for anesthesia unwilling to accept the long-term placement of ureteral stent uncontrolled urinary tract infection","80 Years",{"count":94,"type":21},200,[24],"To conduct a prospective, multi-center study to observe the long-term efficacy and safety of self expanding ureteral stent for treating participants with refractory ureteral stricture.",[98,99,100],"Ureteral Stenosis","Hydronephrosis","Ureteral Stent Occlusion",[102,103,104],"ureteral stone","ureteral stricture","hydronephrosis","2022-07-07",{"date":107,"type":43},"2022-07-13",{"date":109,"type":21},"2022-07-30",{"date":111,"type":21},"2027-07-30",{"name":49,"class":50},""]